Patents by Inventor Mark W. Dewhirst

Mark W. Dewhirst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786595
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: October 17, 2023
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
  • Patent number: 11571587
    Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 7, 2023
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Publication number: 20220062419
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Application
    Filed: April 12, 2021
    Publication date: March 3, 2022
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. Bourke, JR., Zakaryae FATHI, Wayne F. BEYER, JR.
  • Patent number: 11135294
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: October 5, 2021
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
  • Publication number: 20200368547
    Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 26, 2020
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Michael J. THERIEN, Mark W. DEWHIRST, Ian N. STANTON, Jennifer Ann AYRES, Diane Renee FELS, Joseph A. HERBERT
  • Patent number: 10709900
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Patent number: 10596387
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: March 24, 2020
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Harold Walder, Frederic A. Bourke, Zakaryae Fathi, Wayne F. Beyer, Mark W. Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
  • Publication number: 20190168015
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact witht least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Application
    Filed: January 18, 2019
    Publication date: June 6, 2019
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. BOURKE, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Patent number: 10232190
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 19, 2019
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Publication number: 20180311355
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 1, 2018
    Inventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne F. BEYER
  • Patent number: 9907976
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: March 6, 2018
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Publication number: 20170319868
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 9, 2017
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Publication number: 20170283882
    Abstract: This disclosure provides methods and compositions of matter relating to the monitoring of relative concentrations of pairs of isoforms of mRNA or downstream expression products thereof. The methods can include measuring a relative expression level of a pair of mRNA isoforms or downstream expression products thereof and comparing the relative expression level to relative historical or cohort expression levels of the same pair of mRNA isoforms. The result of the comparison can lead to a more accurate prognosis for the subject.
    Type: Application
    Filed: September 8, 2015
    Publication date: October 5, 2017
    Inventors: Timothy J. Robinson, Mark W. Dewhirst
  • Patent number: 9709551
    Abstract: The present invention relates to the innovation that ECFCs are a predictor of the likely result to the exposure of a patient to low dose ionizing radiation by comparing the results of exposure of cells to individuals already exposed to ECFCs.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: July 18, 2017
    Assignee: Creative Scientist, Inc.
    Inventors: Alexander V Kinev, Dora Il'yasova, Mark W. Dewhirst
  • Publication number: 20170115293
    Abstract: Methods for predicting the radiosensitivity of a cancer tumor and treating cancer in a subject are provided. In another aspect, methods of treating cancer in a subject are also provided. The methods may include administering to the subject radiation therapy based on the expression level of no more than 35, 30, 25, 20, 15, 10, or 5 biomarkers in a tumor sample from the subject. The methods of treating cancer in a subject may also include administering a therapeutically effective amount of a FAS agonist and/or a TNFRSF10B agonist to the subject, and administering radiation therapy to the subject.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 27, 2017
    Applicant: DUKE UNIVERSITY
    Inventors: Janet Horton, Jen-Tsan Ashley Chi, Sharareh Reihani, Mark W. Dewhirst
  • Publication number: 20170050046
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photo-activatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 23, 2017
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne F. BEYER, Mark W. DEWHIRST, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
  • Publication number: 20150355164
    Abstract: The present invention relates to the innovation that ECFCs are a predictor of the likely result to the exposure of a patient to low dose ionizing radiation by comparing the results of exposure of cells to individuals already exposed to ECFCs.
    Type: Application
    Filed: January 28, 2014
    Publication date: December 10, 2015
    Applicant: CREATIVE SCIENTIST, LLC
    Inventors: Alexander V Kinev, Dora Il'yasova, Mark W. Dewhirst
  • Patent number: 9056080
    Abstract: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 16, 2015
    Assignee: Duke University
    Inventors: Mark W. Dewhirst, Jonathan S. Stamler, Timothy J. McMahon, Pierre D. Sonveaux
  • Patent number: 8968702
    Abstract: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: March 3, 2015
    Assignee: Duke University
    Inventors: Chuan-Yuan Li, Fang Li, Pierre Sonveaux, Mark W. Dewhirst
  • Publication number: 20140323946
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Application
    Filed: July 9, 2012
    Publication date: October 30, 2014
    Applicants: DUKE UNIVERSITY, IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert